A phase 1b study of the anticancer stem cell agent demcizumab (DEM), pemetrexed (PEM), and carboplatin (CARBO) in pts with first-line nonsquamous NSCLC. This is an ASCO Meeting Abstract from the 2014 ...
In a review published in the journal Genes & Diseases, researchers from ICMR-National Institute of Nutrition (NIN), advocate for the repurposing of non-cancer drugs to target elusive cancer stem cells ...
Cancer stem cells, characterized with self-renewal, differentiation, heterogeneity, plasticity and tumorigenicity, are regulated by intrinsic factors such as signaling pathways, transcription factors, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results